Manufacturer of Controlled Substances; Notice of Application, 14948 [E6-4302]
Download as PDF
<![CDATA[
14948
Federal Register / Vol. 71, No. 57 / Friday, March 24, 2006 / Notices
Dated: February 24, 2006.
Thomas A. Readinger,
Associate Director for Offshore Minerals
Management.
[FR Doc. E6–4303 Filed 3–23–06; 8:45 am]
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
BILLING CODE 4310–MR–P
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on June 13, 2005,
Cerilliant API Services, LLC, 811
Paloma Drive, Suite A, Round Rock,
Texas 78664, made application to the
Drug Enforcement Administration
(DEA) for registration as a bulk
manufacturer of the basic classes of
controlled substances listed in Schedule
I and II; and by letter dated September
2, 2005, to modify its name to Austin
Pharma, LLC.
DEPARTMENT OF THE INTERIOR
Bureau of Reclamation
Upper Rio Grande Basin Water
Operations Review, NM; Notice of
Extension
Bureau of Reclamation,
Interior.
ACTION: Notice of extension of public
comment period for thirty days.
AGENCY:
SUMMARY: Notice is hereby given that
the comment period for the Draft
Environmental Impact Statement (DEIS)
for the Upper Rio Grande Water
Operations Review, DES–05–80, is
extended an additional 30 days to April
20, 2006.
DATES: The end of the public comment
period, as noted in the Federal Register
(71 FR 3323) on January 20, 2006, was
March 21, 2006. The public comment
period is now extended to April 20,
2006.
Written comments on the
DEIS should be addressed to Valda
Terauds, ALB–707, Bureau of
Reclamation, Albuquerque Area Office,
555 Broadway, NW., Suite 100,
Albuquerque, New Mexico 87102;
faxogram (505) 462–3593; e-mail:
vterauds@uc.usbr.gov. Our practice is to
make comments, including names and
home addresses of respondents,
available for public review. Individual
respondents may request that we
withhold their home address from
public disclosure, which we will honor
to the extent allowable by law. If you
wish us to withhold your name and/or
address, you must state this
prominently at the beginning of your
comment. We will make all submissions
from organizations or businesses, and
from individuals identifying themselves
as representatives or officials of
organizations or businesses, available
for public disclosure in their entirety.
FOR FURTHER INFORMATION CONTACT:
Valda Terauds, Resource Management
Planner, (505) 462–3584.
wwhite on PROD1PC61 with NOTICES
ADDRESSES:
Dated: March 7, 2006.
Roger Slater,
Acting Regional Director—UC Region, Bureau
of Reclamation.
[FR Doc. E6–4306 Filed 3–23–06; 8:45 am]
Drug
Schedule
Lysergic acid diethylamide (7315)
Marihuana (7360) .........................
Tetrahydrocannabinois (7370) .....
3,4–Methylenedioxyamphetamine
(7400).
3,4–Methylenedioxy-Nethylamphetamine (7404).
3,4–
Methylenedioxymethamphetamine (7405).
Psilocyn (7438) .............................
Acetyldihydrocodeine (9051) ........
Benzylmorphine (9052) ................
Codeine-N-oxide (9053) ...............
Cyprenorphine (9054) ..................
Desomorphine (9055) ...................
Etorphine (9056) ...........................
Codeine methylbromide (9070) ....
Dihydromorphine (9145) ...............
Heroin (9200) ...............................
Hydromorphinol (9301) .................
Methyldihydromorphine (9304) .....
Morphine methylbromide (9305) ..
Morphine-N-oxide (9307) .............
Alphamethadol (9605) ..................
Normethadone (9635) ..................
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Cocaine (9041) .............................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Benzoylecgonine (9180) ...............
Ecgonine (9180) ...........................
Hydrocodone (9193) .....................
Levomethorphan (9210) ...............
Methadone (9250) ........................
Methadone intermediate (9254) ...
Morphine (9300) ...........................
Thebaine (9333) ...........................
Levo-alphacetylmethadol (9648) ..
Oxymorphone (9652) ...................
Poppy Straw Concentrate (9670)
Alfentanil (9737) ...........................
Remifentanil (9739) ......................
Sufentanil (9740) ..........................
Carfentanil (9743) .........................
Fentanyl (9801) ............................
BILLING CODE 4310–MN–P
VerDate Aug<31>2005
18:26 Mar 23, 2006
Jkt 208001
PO 00000
Frm 00117
Fmt 4703
Sfmt 4703
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
In reference to drug code 7360
(Marihuana), the company plans to bulk
manufacture cannabidiol as a synthetic
intermediate. This controlled substance
will be further synthesized to bulk
manufacture a synthetic THC (7370). No
other activity for this drug code is
authorized for this registration.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
may be addressed, in quintuplicate, to
the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration,
Washington, DC 20537, Attention: DEA
Federal Register Representative, Liaison
and Policy Section (ODL); or any being
sent via express mail should be sent to
DEA Headquarters, Attention: DEA
Federal Register Representative/ODL,
2401 Jefferson-Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than May 23, 2006.
Dated: March 20, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E6–4302 Filed 3–23–06; 8:45 am]
BiLLiNG CODE 4410–09–P
DEPARTMENT OF LABOR
Office of the Secretary
Submission for OMB Review:
Comment Request
March 17, 2006.
The Department of Labor (DOL) has
submitted the following public
information collection requests (ICR) to
the Office of Management and Budget
(OMB) for review and approval in
accordance with the Paperwork
Reduction Act of 1995 (Pub. L. 104–13,
44 U.S.C. chapter 35). A copy of each
ICR, with applicable supporting
documentation, may be obtained by
contacting Darrin King on 202–693–
4129 (this is not a toll-free number) or
e-mail: king.darrin@dol.gov.
Comments should be sent to Office of
Information and Regulatory Affairs,
Attn: OMB Desk Officer for the
Occupational Safety and Health
Administration (OSHA), Office of
Management and Budget, Room 10235,
Washington, DC 20503, 202–395–7316
E:\FR\FM\24MRN1.SGM
24MRN1
]]>Agencies
[Federal Register Volume 71, Number 57 (Friday, March 24, 2006)]
[Notices]
[Page 14948]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-4302]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Sec. 1301.33(a) of Title 21 of the Code of Federal
Regulations (CFR), this is notice that on June 13, 2005, Cerilliant API
Services, LLC, 811 Paloma Drive, Suite A, Round Rock, Texas 78664, made
application to the Drug Enforcement Administration (DEA) for
registration as a bulk manufacturer of the basic classes of controlled
substances listed in Schedule I and II; and by letter dated September
2, 2005, to modify its name to Austin Pharma, LLC.
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Lysergic acid diethylamide (7315).......... I
Marihuana (7360)........................... I
Tetrahydrocannabinois (7370)............... I
3,4-Methylenedioxyamphetamine (7400)....... I
3,4-Methylenedioxy-N-ethylamphetamine I
(7404).
3,4-Methylenedioxymethamphetamine (7405)... I
Psilocyn (7438)............................ I
Acetyldihydrocodeine (9051)................ I
Benzylmorphine (9052)...................... I
Codeine-N-oxide (9053)..................... I
Cyprenorphine (9054)....................... I
Desomorphine (9055)........................ I
Etorphine (9056)........................... I
Codeine methylbromide (9070)............... I
Dihydromorphine (9145)..................... I
Heroin (9200).............................. I
Hydromorphinol (9301)...................... I
Methyldihydromorphine (9304)............... I
Morphine methylbromide (9305).............. I
Morphine-N-oxide (9307).................... I
Alphamethadol (9605)....................... I
Normethadone (9635)........................ I
Amphetamine (1100)......................... II
Methamphetamine (1105)..................... II
Cocaine (9041)............................. II
Codeine (9050)............................. II
Dihydrocodeine (9120)...................... II
Oxycodone (9143)........................... II
Hydromorphone (9150)....................... II
Benzoylecgonine (9180)..................... II
Ecgonine (9180)............................ II
Hydrocodone (9193)......................... II
Levomethorphan (9210)...................... II
Methadone (9250)........................... II
Methadone intermediate (9254).............. II
Morphine (9300)............................ II
Thebaine (9333)............................ II
Levo-alphacetylmethadol (9648)............. II
Oxymorphone (9652)......................... II
Poppy Straw Concentrate (9670)............. II
Alfentanil (9737).......................... II
Remifentanil (9739)........................ II
Sufentanil (9740).......................... II
Carfentanil (9743)......................... II
Fentanyl (9801)............................ II
------------------------------------------------------------------------
The company plans to manufacture the listed controlled substances
in bulk for distribution to its customers.
In reference to drug code 7360 (Marihuana), the company plans to
bulk manufacture cannabidiol as a synthetic intermediate. This
controlled substance will be further synthesized to bulk manufacture a
synthetic THC (7370). No other activity for this drug code is
authorized for this registration.
Any other such applicant and any person who is presently registered
with DEA to manufacture such a substance may file comments or
objections to the issuance of the proposed registration pursuant to 21
CFR 1301.33(a).
Any such written comments or objections being sent via regular mail
may be addressed, in quintuplicate, to the Deputy Assistant
Administrator, Office of Diversion Control, Drug Enforcement
Administration, Washington, DC 20537, Attention: DEA Federal Register
Representative, Liaison and Policy Section (ODL); or any being sent via
express mail should be sent to DEA Headquarters, Attention: DEA Federal
Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria,
Virginia 22301; and must be filed no later than May 23, 2006.
Dated: March 20, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E6-4302 Filed 3-23-06; 8:45 am]
BiLLiNG CODE 4410-09-P
